drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA) on tumor cells, leading to T-cell activation and cytotoxic killing; administered IV or IP after lymphodepletion to promote expansion and persistence.
nci_thesaurus_concept_id
C188356
nci_thesaurus_definition
A preparation of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CEA CAR T cells specifically recognize and induce selective toxicity in CEA-expressing tumor cells. CEA, a member of the CEA family of proteins, plays a key role in cell migration, cell invasion and cell adhesion, and is overexpressed by a variety of cancer types.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Intraperitoneal
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds carcinoembryonic antigen (CEA) on tumor cells, leading to antigen-specific T‑cell activation, proliferation, cytokine release, and cytotoxic killing of CEA-expressing cancer cells; lymphodepleting chemotherapy is used to enhance CAR-T expansion and persistence.
drug_name
CEA CAR-T cells
nct_id_drug_ref
NCT06010862